WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000025773) PHARMACEUTICAL COMBINATION OF MILDRONATE AND ENALAPRIL
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/025773    International Application No.:    PCT/LV1999/000005
Publication Date: 11.05.2000 International Filing Date: 27.10.1999
Chapter 2 Demand Filed:    26.05.2000    
IPC:
A61K 31/40 (2006.01), A61K 45/06 (2006.01)
Applicants: KALVINSH, Ivars [LV/LV]; (LV).
VEVERIS, Maris [LV/LV]; (LV).
BUNDULIS, Juris [LV/LV]; (LV).
SKARDA, Ilze [LV/LV]; (LV)
Inventors: KALVINSH, Ivars; (LV).
VEVERIS, Maris; (LV).
BUNDULIS, Juris; (LV).
SKARDA, Ilze; (LV)
Agent: FOGEL, Abraham; Alfa-Patents Viranes iela 2 LV-1073 Riga (LV).
MADGWICK, Paul; Ruschke Hartmann Becker Fienzenauerstrasse 2 D-81679 München (DE)
Priority Data:
P-98-252 29.10.1998 LV
Title (EN) PHARMACEUTICAL COMBINATION OF MILDRONATE AND ENALAPRIL
(FR) COMBINAISON PHARMACEUTIQUE DE MILDRONATE ET D'ENALAPRIL
Abstract: front page image
(EN)Pharmaceutical composition, containing 3-(2,2,2-trimethyldrazinium) propionate dihydrate or Mildronate and angiotensin converting enzyme (ACE) inhibitor, as combined preparation for treatment of cardiovascular diseases. It is proposed to use (S)-1-{N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl}-L-proline or Enalapril as ACE inhibitor. The advisable proportion of Mildronate and Enalapryl in the combination is within the range from 8:1 to 12:1.
(FR)Composition pharmaceutique contenant 3-(2,2,2-triméthylhydrazinium) proponiate dihydrate, ou mildronate, et un inhibiteur d'enzyme de conversion de l'angiotensine (ACE), en tant que préparation combinée destinée au traitement de maladies cardiovasculaires. Il est proposé d'utiliser (S)-1-{N-[1-(éthoxycarbonyl)-3-phénylpropyl]-L-alanyl}-L-proline, ou énalapril, en tant qu'inhibiteur ACE. On recommande la combinaison de mildronate et d'énalapril dans la proportion de 8:1 à 12:1.
Designated States: CA, JP, UA, US.
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)